Welcome to article directory Mesothelioma Cancer Law. Here You can find interesting and useful information on most popular themes.

There are 673 published articles and 431 registered authors in our article directory.

Recent Articles

Mesothelioma Lawyer Breaking News

Mesothelioma Lawyer : Simian virus 40, or SV40, is a virus that has been asso­ciated with the development of malignant mesothe­lioma. This virus is found in rhesus monkeys and is now widespread among humans. The way this virus was transferred from monkeys to humans is uncertain, but it is postulated that some of the transfer occurred from 1954 to 1963 through SV40-contaminated polio vaccines administered worldwide. Those people who received the injectable form of the polio vaccine are believed to be those at greatest risk. This vaccine doesn’t folly explain the transfer of this virus, because many humans who could not have received the contaminated vaccines are now infected with the SV40 virus. One theory that has been proposed is that the SV40 virus continues to be transferred from monkeys to humans or that humans can pass the virus from person to per­son. Propecia Lawsuit

For more information on Mesothelioma Lawyer follow us on our RSS Feeds.

The latter theory has been supported by data showing that SV40 can be excreted in human feces, breast milk, and semen. It is unlikely that this virus acts alone in the development of mesothelioma as most cancers have multiple risk factors associated with their development, and most mesotheliomas occur in asbestos exposed individuals. Instead, it is more likely that asbestos and SV40 may act together to develop into mesothelioma. Although rare, cases of mesothelioma have been found following radiation exposure to the chest and abdomen. These individuals were usually treated in the past with radiation therapy for a malignancy of the lymph glands known as lymphoma.

Lastly, there is an indication that a person’s own genes can play an important role in determining who is sus­ceptible, or vulnerable, to these mineral fibers and will then develop mesothelioma. It is hoped that doctors will be able to find the specific susceptibility gene in the future and that this may lead to the development of new prevention and treatment strategies to better control this disease. Exposure to asbestos is the link to the development of mesothelioma. People who end up with this disease usually have had some type of previous exposure to asbestos. How this works is not fully understood. It is thought that asbestos fibers are inhaled and first travel through the upper air passages, which include the throat, the trachea (windpipe), and the large bronchi (large breathing tubes of the lungs). These airways are lined with mucus, and therefore most of the fibers are cleared from these upper airways by sticking to this mucus and being coughed up or swallowed. When the fibers continue to travel and reach the small airways (the alveoli), the body’s immune system is able to sur­round, engulf, and remove the smaller fibers by a process known as phagocytosis. Actos Lawsuit

 

Information from other sources on Mesothelioma Lawyer

The large, long, thin fibers cannot be cleared as easily and may eventually reach the pleura (the lining of the lung and the chest wall), where they may irritate and injure the cells and lead to the development of calcium containing plate­like structures on the pleural lining (pleural plaques), fibrosis (scar tissue formation), or mesothelioma. These same asbestos fibers can also damage cells in the lung itself, which can lead to asbestosis (scar tissue in the lung) and/or lung cancer. Patients with these pleu­ral plaques seem to be at highest risk for developing mesothelioma.

The best way to prevent mesothelioma is to decrease one’s exposure to asbestos in the workplace, at home, and in the environment. The federal government is responsible for developing regulations that deal with asbestos exposure in the workplace. The agency that issues these regulations is known as the Occupational Safety and Health Administration (OSHA). Employ­ers are required to follow these regulations, and there­fore workers who are concerned about asbestos exposure should be discussing these concerns with their employers or union. Also, employees should be using all protective equipment provided to them by their employers and following recommended safety procedures and practices while at work.

Our use of the term or terms Mesothelioma Lawyer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Mesothelioma Lawyer visit our site often.

Mesothelioma Lawyer

Posted in Mesothelioma Cancer Law | Tagged , |

Actos and Bladder Cancer Scoop

Actos and Bladder Cancer: For the practicing urologist it is often difficult to inform the patient on muscle invasive bladder cancer and the often need for radical surgery and some kind of urinary diversion to follow; however, it is even more elaborate to do so in case of a nonmuscle invasive tumor where the evidence calls for radical treatment. In Chap. 15, Waalkes, Merseburger, and Kuczyk present pathologies where a radical treat­ment is strongly advised.In Chapters 16-18 focus various aspects of cystectomy. In Chap. 16, radical surgery of the bladder is discussed by Dr. Gschwend. The improvement in surgical techniques had led this formerly challenging procedure into a more standardized one. Chapter 17 includes urinary diversion by Drs. Richard and Stefan Hautmann. The ileal neobladder has become one of the worldwide chosen procedures for con­tinent orthotopic urinary diversion. Chapter 18, laparoscopic cystectomy by Dr. John, is the latest evolvement in bladder surgery and covers innovative tech­niques as well as the well-established surgical routines in radical treatment of invasive bladder cancer.

 

More information on Actos and Bladder Cancer

In 2010, only 5% of all urologists are performing neoadjuvant chemotherapy in patients with muscle invasive bladder cancer, hence the 5% survival benefit in5 years and possible down staging of the tumor. Dr. Sherif guides us along the current literature and discusses the pros and cons of the neoadjuvant chemotherapy. Diagnosis and treatment of upper tract tumors is challenging and Chap. 20 by Dr. Remzi discusses the basics as well as recent advances in this field. In Chap. 21, De Santis and Bachner focus on the development and optimal use of new regimens for systemic agents as well as standard treatment options for the treatment of meta­static urinary carcinoma in the areas of targeted drugs. Options for “unfit” patients and elderly as well as in second-line setting are discussed. In Chap. 22 non-TCC tumors: Diagnosis and treatment is discussed by Dr. Abol-Enein. He focuses mainly on the squamous cell and adenocarcinoma of the bladder.

We hope that this brief synopsis of the topics covered in each chapter will encourage the readers to use this book for a general read on bladder cancer and as a reference guide for specific molecular and clinical aspects of bladder cancer. We again thank the authors for contributing to this project. We thank our Mr. Michael Koy, production editor at Springer and Spi Editorial Department, India for helping us in the publication of this book. We would like to thank Brian Halm of Springer for helping us with the publication of this book.

 

Information from other sources on Actos and Bladder Cancer

Abstract Bladder cancer (BC) is a worldwide health problem. In 2006 in Europe, there were an estimated 104,400 incident cases of BC diagnosed (82,800 in men and 21,600 in women) that represent a 6.6% of the total cancers in men and 2.1% in women.Tobacco use is a major preventable cause of death, and especially involved with BC carcinogenesis. Tobacco smoking is the most well-established risk factor for BC, causing around 50%-65% of male cases and 20%-30% of female cases.

Occupational exposure has been considered the second most important risk factor for BC. Work related cases account for a 20%-25% of all BC cases in several series.

In addition, chronic urinary tract infection had been related to BC, particularly, with invasive squamous cell carcinoma. Bladder schistosomiasis has particularly- been considered by the international agency for research on cancer (IARC) as a definitive cause or urinary BC with an associated fivefold risk.

 

Our use of the term or terms Actos and Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos and Bladder Cancer visit our site often.

http://www.seedol.com

Posted in Mesothelioma Cancer Law | Tagged , |

Multaq and Liver Damage Information

Multaq and Liver Damage: The most effective treatment of chronic HCV is antiviral ther- apy—that is, medication that targets a virus. Interferon, a widely known antiviral discussed earlier in this chapter, is the treatment of choice for chronic HCV. Pegylated interferon in combination with ribavirin-—-the most common treatment-—is the most effective treatment for chronic hepatitis C, but the side effects can be substantial. Flulike symp­toms (fever, chills, muscle and joint pain, fatigue, weakness) are common, and doctors will prescribe medications to combat these symptoms if they become debilitating. It is also important for patients to maintain their activity levels to build a little muscle and be able to muster the energy to get through the day. Adequate fluid intake is also essential. This is a simple and often overlooked strategy. Many patients report that substantially increasing their daily fluid intake is the most effective method in combating the fiulike side effects that plague pegylated interferon therapy.

Depression, insomnia, irritability, and even confusion are expe­rienced by more than half of patients undergoing interferon ther­apy. The depression is considered to be somewhat different from classic major depression, but afflicted patients may benefit from a course of antidepressants such as citalopram (brand name Celexa) or sertraline (brand name Zoloft).

Other side effects that don’t seem to follow any regular pattern include headaches, vision problems or dry eyes, weight changes, brictle nails, insomnia, changes in blood levels, a burning sen­sation in the mouth (known as stomatitis), decreased sex drive, and menstrual irregularities. To some degree, these symptoms are manageable. But in some patients, the side effects can be severe, and supportive medications are able only to “take the edge off” Although treatment may be difficult, physicians who regularly treat chronic hepatitis C are well versed in managing side effects. Key to successful outcome is maintaining the proper dose of medication to ensure that patients have the best possible chance to permanendy rid their bodies of the virus.

For more information on Multaq and Liver Damage follow us on our RSS Feeds.

Because of chronic HCV’s complicated makeup—-the genotypes outlined above—pegylated interferon therapy must be custom­ized to each patient. Therapy duration is dictated by the genotype. Pegylated interferon is used, if possible, in combination with riba­virin. The only time ribavirin is not used is when there is a medical contra-indication, such as chronic kidney (renal) failure requiring dialysis or a severe allergy to ribavirin. How well the patient responds to antiviral treatment is determined by two simple lab tests. The first is the alanine transaminase (ALT) test. When the ALT decreases and returns to a normal level, it is referred to as a biochemical response. This does not always occur, but it is a con­sidered a good sign. The most important test in determining treat­ment success is the HCV RNA, or viral load test. The decline in the viral load is the most crucial aspect of therapy. Typically, a patient is tested at the outset, to determine a baseline or pre-treatment viral load, and then retested to measure against the subsequent viral loads as treatment progresses.

Four weeks after treat­ment begins, first viral load is measured. If a patient’s viral load is un-detectable at one month, the results are called a rapid virologie response, or RVR. People who achieve an RVR are called super responders. They have an excellent chance of eradicating the virus after they complete their treatment. A small subset of patients who achieve an RVR can sometimes stop treatment early. The deter­mination to stop treatment early is made on a case-by-case basis, and the patient should be informed of the pros (shorter treatment duration, lower cost, and less side effects) and cons (slightly lesser chance for sustained response) of this approach.

Information from other sources on Multaq and Liver Damage

After 12 weeks (three months) of therapy, viral load is mea­sured again. The outcome of this viral load test is referred to by different names, depending on the results. When the virus is unde­tectable after three months of therapy, the condition is described as a complete early virologie response (cEVR). If the viral load has declined by two logs but is still detectable, the data is referred to as a partial early virologic response (pEVR).

People who achieve a partial or complete early virologic response continue drug therapy. Those who do not achieve a two-log reduc­tion after 12 weeks are called nonresponders (NRs). Unfortunately, nonresponders have less than a 3 percent chance of achieving a sustained viral response even if they complete the full course of therapy. Therefore, therapy is stopped for nonresponders after three months if they do not obtain a two-log reduction.

For patients who remain on therapy, the next viral load test is taken after six months (24 weeks) of therapy. If this test indicates a detectable viral load, as a rule, treatment is stopped because these patients will not achieve treatment success even if they complete a full 48 weeks of therapy.

After 48 weeks of pegylated interferon and ribavirin, another viral load test is performed. Referred to as the end-of-treatment response (ETR), this viral load measurement marks the end of therapy and the beginning of a waiting game. For treatment to be considered a success, the viral load must remain negative for at least six months after the end of therapy. Unfortunately, some patients relapse and test positive during this six-month period. Relapsers should follow up and discuss their situation with a hepatologist and consider options such as enrollment in research clinical trials of new and experimental therapies can be considered.

Our use of the term or terms Multaq and Liver Damage is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Multaq and Liver Damage visit our site often.

Multaq and Liver Damage

Posted in Mesothelioma Cancer Law | Tagged , |

Actos Warning News Flash

Actos Warning : Recently, a metaanalysis of observational studies on cigarette smoking and cancer from 1961 to 2003 has been published. The authors extracted data from 254 reports published during that period of time and included them in the 2004 IARC Monograph on Tobacco Smoke and Involuntary Smoking. The analyses were arried out on 216 studies with reported estimates for current and/or former smokers. The pooled risk estimates for BC demonstrated significant association for both current and former smokers. In an analysis of 21 studies, the overall rela­tive risk calculated for current smokers was 2.77 [95% confidence interval (CI) 2.17, 3.54]; while from the analyses of 15 studies, the overall relative risk calcu­lated for former smokers was 1.72 (95% CI 1.46, 2.04) (Gandini et al. 2008).

 

More information on Actos Warning

In a pooled analysis of 11 case-control studies regarding cigarette smoking and BC, the following three variables were analyzed: duration of smoking, average number of cigarettes smoked per day, and time since quitting smoking. The popula­tion consisted of 2600 cases and 5524 controls. An increasing risk of BC was observed with increasing duration of smoking, which appeared to be linear. The relative increase was approximately 100% after 20 years smoking and reaches to 400% after 50 years smoking. In addition, a relationship was observed between the number of cigarettes smoked per day and BC.

The OR increased to nearly threefold for those who smoked between 15 and 20 cigarettes per day, after which a plateau in the risk graph was observed. They concluded that the duration of smoking habit and not the amount of cigarettes smoked per day was the main determining factor for BC. An immediate decrease in risk of BC was observed for those who quit smoking. This reduction was about 40% within 1-4 years of quitting smoking and reaches 60% after 25 years of cessation. However, the risk does not reach the level of nonsmokers even after 25 years. This suggests that tobacco has a late effect in the carcinogenesis of BC, but the fact that this risk does not reach the levels of nonsmokers until 25 years after quitting smoking suggests that tobacco may also be involved in an early irreversible stage in the carcinogenesis process (Brennan et al. 2000).

Information from other sources on Actos Warning

Other issues as type of tobacco could be taken into account. Six studies have published a significant higher risk of BC for the blacks who are cigarette smokers compared to smokers of otherraces. Also, case-control studies suggest a strong evidence of a carcinogenic effect of cigars and pipe, which is comparable to that of cigarettes (Boffetta 2008). The mode of inhalation of tobacco smoke has been related to BC risk, as well. In a case-control study of smoking and BC from Spain that included 1219 cases and 1271 controls, they concluded that the former and current smokers experienced risks of BC three to seven times higher than nonsmok­ers, respectively.

In addition, they found that the risk was higher for subjects who inhaled into the throat or chest [OR 4.8 (95% CI 2.3-9.9)] compared with those who inhaled only into the mouth [OR 10.0 (95% CI 6.7-15.0)], at each level of duration (Samanic et al. 2006).

Taking into account that current smokers have higher risk of BC than nonsmokers, and that this risk decreases by 40% after 1-4 years of quitting smoking, the promotion of cessation of smoking would allow reducing the incidence of BC in men and women.

Internationally, there is a general agreement on the broad strategy needed to successfully combat the tobacco epidemic.

 

Our use of the term or terms Actos Warning is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Warning visit our site often.

http://www.seedol.com

Posted in Mesothelioma Cancer Law | Tagged , |

Actos Lawyer Headlines

Actos Lawyer: The medical history of those with bladder cancer varies. For many patients, the first clue is blood in the urine, while in others, it may be an alteration in urination. Sometimes a tumor is found inadvertently on an X ray or ultrasound exam. In all cases, an initial assessment is implemented by the urologist. In this chapter, we will review the presenting findings of those with bladder cancer and how they are initially “worked up.” A sign is a physical finding from an underlying disease or disorder which can be noted by the individual or the physician. A symptom is something the individual feels or experiences from a disease. A clinical sign is a physical finding, while a symptom is something the individual experiences.

For more information on Actos Lawyer follow us on our RSS Feeds.

Absolutely! Approximately three quarters of individuals with bladder cancer initially present with blood in their urine. The blood may be visible to the naked eye (gross hematuria), or seen with a microscope only (microscopic hematuria). In the case of gross hematuria secondary to bladder cancer, it is often total (throughout the entire stream) and may be intermittent. Generally, there is no pain associated with it. I have seen many patients over the years who had gross hematuria months earlier who falsely assumed their condition was not serious since the bleeding stopped and there was no pain, only to come in later with recurrent bleeding, their tumors needlessly more advanced. When an individual experiences gross hematuria, a work up is a must! Gross hematuria at times can become quite severe to the point blood clots can restrict the flow of urine. What could have been an elective assessment then becomes a mad dash to the emergency room for catheterization (passing a tube into the bladder) and irrigation or an emergency procedure. Of course, there are other causes for gross hematuria, such as urinary infections, kidney stones or tumors in the kidney, all of which require assessment.

Information from other sources on Actos Lawyer

If a urine dipstick is positive for blood, it is recommended to check the urine under a microscope. The urine is first spun down to separate out the sediment and is then examined under the high power lens. If there are more than 3 red blood cells per high power field it is felt to be significant. If there are no other reasons for the presence of blood such as a urinary infection, the urine should be rechecked. If there is a persistent presence of significant microscopic hematuria, an assessment is recommended. When there is a large amount of microscopic hematuria, especially in older individuals with risk factors for bladder cancer, there is no need to repeat the urinalysis as a workup should be done.

A small amount of microscopic hematuria in an individual without symptoms (asymptomatic microscopic hematuria) can be found in many healthy individuals. It has been estimated that up to 10% of the population has asymptomatic microscopic hematuria. In brief, the older you are (generally over the age of 40), the more risk factors you have (smoking, occupational exposure), and the more red blood cells present, the more likely serious pathology (disease of the urinary tract including bladder cancer) will be found. If you have persistent microscopic hematuria without a known cause, a urologic assessment is recommended.

Our use of the term or terms Actos Lawyer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Lawyer visit our site often.

Actos Lawyer

Posted in Mesothelioma Cancer Law | Tagged , |

Multaq Lawyer Info

Multaq Lawyer: Although no treatment exists for HAV, it is important to treat the symptoms. Patients experiencing fatigue should rest and not to push themselves. All HAV patients must drink plenty of fluids because dehydration can easily develop as a complication, espe­cially if the patient has had diarrhea. The good news about HAV is that if a person receives the proper vaccine series, the disease is almost always preventable. The HAV vaccine series has been used extensively worldwide and has proved to be a safe and extremely effective vaccine.

The first hepatitis virus to be discovered, hepatitis B (HBV), has infected an estimated 2 billion people worldwide. About 300 million are chronic carriers of the virus, including about 1.25 million Americans. HBV can be deadly; its complications kill about 1 million people every year, and it is the most prevalent cause of cirrhosis and liver cancer in the world, particularly in Africa and Southeast Asia. Yet most people infected with HBV lead fully normal lives.

The HBV virus can be found in body fluids, including saliva, blood, tears, and breast milk, though it is transferred between people only through blood and semen. Casual contact, such as hugging or shaking hands, does not spread the disease; in fact, not everyone infected with HBV is contagious. HBV can be con­tracted only through sexual contact, a blood exchange, or from a pregnant mother to her fetus—a method of transmission common in Africa and Asia.

For more information on Multaq Lawyer follow us on our RSS Feeds.

Before 1975, blood and platelets collected from blood donors (during blood drives, for example) were not screened for HBV so transfusions once accounted for many HBV infections in this country. Today, donated blood is tested for HBV, but the virus continues to be transferred through more subtle blood exchanges, such as when an infected person shares a razor or nail clippers, or exposes another person through a bleeding skin condition.

Needles used for tattooing and acupuncture can also be contaminated with blood infected with HBV. People diagnosed with hepatitis B need to take special care to cover any bleeding spots, and everyone should avoid contact with used needles. The HBV virus can live on an open surface, including needles, for up to a week.

Immunization is key to preventing hepatitis B. People who have been vaccinated are virtually 100 percent protected, so HBV is a disease that could be eliminated. For now, though, its important for individuals at risk to take precautions. Health-care workers, any­one who received a blood transfusion before 1975, and anyone who lives with (or is sexually intimate with) an HBV-infected person are candidates for screening. In fact, it is recommended that sexually active homosexual men, intravenous drug users, dialysis patients, and anyone who has more than one sex partner within six months be screened for HBV. Anyone who receives results that indicate he or she is not immune should receive the vaccine series.

Information from other sources on Multaq Lawyer

Acute hepatitis B, or HBV that lasts less than six months, is no longer prevalent in the United States, probably the result of early vaccinations. It does occasionally occur, however, and its flulike symptoms—fever, abdominal upset, nausea, decreased appetite, vomiting, and changes in the way things taste and smell—resem­ble symptoms associated with other hepatitis infections. In some cases, the individual experiences symptoms that make it clear the immune system is fighting off the HBV, such as muscle and joint aches, too much protein in the urine, or a rash.

Our use of the term or terms Multaq Lawyer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Multaq Lawyer visit our site often.

Multaq Lawyer

Posted in Mesothelioma Cancer Law | Tagged , |

Actos Bladder Cancer News Flash

Actos Bladder Cancer : Bladder tumor “seeding” may occur during the procedure. As the tumors are resected, cancer cells are released into the irrigant which fills the bladder. These cells may implant in other areas of the bladder traumatized during the procedure. It should be understood that the bladder is generally filled with urine, and tumor cells can naturally implant at other locations even without surgery. Implantation can be lessened during surgery by avoiding injury to other bladder areas and by the use of adjuvant intravesical chemotherapy. There have been numerous studies over the past decade showing a number of chemotherapy agents can be effective in decreasing initial tumor recurrence, possibly by preventing seeding. Reduction in recurrence may however be short lived.

Previously, it was common practice to obtain multiple random bladder biopsies at the time of initial tumor resection. This was recommended to rule out the possibility of hidden CIS. Understanding these biopsy sites may increase the possibilities of tumor recurrence by tumor seeding, biopsies are now often limited to areas adjacent to the tumors removed and suspicious appearing areas only. CIS can be ruled out by using cytology, or by obtaining biopsies during future cystoscopy after the tumor has already been removed. When dealing with low grade tumors, random biopsies of the bladder will rarely show cancer.

After your procedure, depending on the level of anesthesia and the extent of surgery, you will be brought either to the recovery room or back to the area where you were first prepared for your procedure. You will be released to home only when you have fully recovered from you anesthetic and are doing well. The recurrence rate for superficial bladder cancer can be as high as 60-90%. Recurrences can cause bleeding and other difficulties and are best handled sooner rather than later. In addition, depending on the initial tumor grade and stage, progression to a more serious form of bladder cancer is an ongoing concern. Surveillance cystoscopy is therefore recommended. Cystoscopy is still the best means to check for recurrent disease. It is however, an invasive procedure and should be accomplished only as often as required. For solitary, low grade, non invasive disease, follow up cystoscopy can be accomplished with the flexible cystoscope if available. If negative at three months, further cystoscopic exams can be done yearly and eventually lengthened even further. For those with multiple tumors, large tumors, high grade tumors or those who also have CIS, frequent cystoscopies, initially every three months are called for. As long as there are no recurrences, the time between cystoscopies can be lengthened. Cytology can also be utilized to reduce the number of cystoscopies. If recurrence or progression does occur, heightened scrutiny is again called for.

More information on Actos Bladder Cancer

Adverse reactions are side effects of treatment. Approximately 95% of individuals will tolerate treatments well. Adverse reactions may be mild. Common reactions include cystitis (inflammation of the bladder characterized by burning on urination), hematuria, mild fever, malaise, and nausea. These symptoms generally pass without any treatment. For bothersome symptoms, various medications may prove helpful. Your physician can prescribe medication for burning or urinary frequency. For those with persistent cystitis, antibiotics can be utilized. For individuals experiencing severe symptoms lasting more than 48 hours, isoniazid, an anti-tuberculous drug can be prescribed.

A short course of 3 days, starting the day before the next dose of BCG can be used to prevent severe side effects. Fortunately severe reactions resulting in sepsis, a life threatening condition characterized by high fever, chills and drop in blood pressure, is exceedingly rare. Sepsis would be treated in a hospital with triple anti-tuberculous drugs, steroids, and broad spectrum antibiotics. There are other serious adverse reactions which may require dose reduction or discontinuation. These are all rare and include: inflammation of the prostate, persistent hematuria, hepatitis, inflammation of the testicles and or epididymis, bladder contraction, ureteral obstruction, joint pain or inflammation of the lungs.

Recurrence of bladder cancer after the initial induction course, or relapse after complete response, would indicate failure of therapy. When two or more courses result in recurrence or when recurrence develops during the first six to twelve months after induction and maintenance therapy, patients generally are felt to have disease which is at higher risk for progression. A high percentage of patients who are complete responders remain tumor free for up to five years. However, with the passage of more time, additional patients will have late recurrences. For those with late recurrences (two to three years after therapy), most will respond to repeat BCG therapy.

Information from other sources on Actos Bladder Cancer

Invasive bladder cancer is often recognizable to the urologist by its appearance during cystoscopy. These cancers are generally large, sometimes multi-focal, and solid in appearance as compared to the fine papillary appearance of superficial bladder cancers. During the transurethral resection of the tumor, the urologist can generally tell the tumor is invading into the deeper portions of the bladder wall.

The pathologist’s report will then indicate the grade of the cancer and the depth of invasion. If the tumor invades into muscle, it is an invasive tumor. Further staging would then include a CT Scan or MRI to assess local contiguous spread, lymph node spread, or more distant spread of the cancer. A chest X ray is also routine. If there are any suspicious areas, a CT Scan of the chest is ordered. A bone scan is generally not required unless the individual has had a new onset of bony pain that is not explained by injury or arthritis.

Our use of the term or terms Actos Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Bladder Cancer visit our site often.

http://www.seedol.com

Posted in Mesothelioma Cancer Law | Tagged , |

Trans Vaginal Mesh Lawsuit Legal Action

Trans Vaginal Mesh Lawsuit: Some women wear pads to protect their underwear and clothes from urine leakage. Your doctor will probably ask you about this during the office visit. The size and absorbency of pads vary, as does die frequency that women change them during the day. In order to accurately measure the amount of urine you may be losing during die day, some doctors ask you to do a pad count For a day or two before your appointment, you will be asked to keep all the pads you use in a sealed plastic bag and bring them, along with one dry pad, to the doctor’s office. This is not the most pleasant task, but it does tell the doctor exactly how much urine you are losing during the day. We weigh the wet pads, then the single dry one, and calcu­late how much urine you have lost. In addition to measuring the number of pads you use during a day, the test can also calculate if whatever treatment we prescribe actually decreases the amount of urine lost.

In order for us to understand what is causing your incontinence, we sometimes need to figure out if the bladder muscle is working properly. The test for this is known as urodynamics, or UDS for short. Despite the peculiar name, this has nothing to do with jet planes or aerodynamics. The term urodynamics implies that we are able to see the bladder (uro), in action (dynamic). The muscular sac we call the bladder is supposed to stay relaxed and then com­fortably expand while it collects and stores urine made by the kid­neys. The bladder is supposed to work without any effort, or even awareness, on your part. Then, when you are ready to urinate, it should contract and force the urine out. The urodynamic study allows us to measure the way the bladder works: Does it fill up without the contractions associated with overactivity? Does it con­tract properly and at the right time? Can the bladder hold a reason­able amount of urine? Does it hold too little urine? Too much? When it contracts, does it get all the urine out?

For more information on Trans Vaginal Mesh Lawsuit follow us on our RSS Feeds.

UDS testing allows us to answer these questions. Some women may need to have UDS testing done, especially if the diagnosis is not clear to the doctor after the initial tests described above. UDS testing is performed in the office, takes about one hour, and is painless. Your doctor will ask you to undress from the waist down and wrap a sheet around your waist. First you will sit in a special chair that supports your back, buttocks, and legs in a comfortable position. This chair allows your doctor to tilt you back to a lying po­sition in order to perform the first part of the testing. Then, with­out your having to move, you can be tilted to a sitting position to see if your bladder functions any differently while you are up­right—as you are for most of the day. The first part of the testing involves urinating into a specialized basin that measures how fast or slowly the urine comes out of your bladder. If something is blocking the urine, such as scarring inside the urethra or a bladder muscle that isn’t working properly, the flow will be slow.

You should not be able to feel anything until your bladder gets filled to the point where you would normally have to urinate. Your doctor will ask you to tell us when this is. Then your doctor will ask you to cough (or bear down) after the addition of every 3 ounces of fluid from that point forward, to see if you leak. Leaking is a sign of having stress incontinence. Your doctor will continue to fill your bladder and ask you to say when you are really full—the point when, if you were driving, you might pull off the road to find a bathroom. Shortly thereafter you will feel that you cannot hold any more, and the test will be stopped. The computer measures how much fluid has been put into the bladder and what the pres­sure is in the bladder as it fills up.

Information from other sources on Trans Vaginal Mesh Lawsuit

Normally, the bladder expands quietly as it fills, without any contractions at all, until you are ready to empty it. For some women, however, an overactive bladder contracts during the time it is filling. These contractions can be seen on the computer and are recorded for later analysis. An overactive bladder is usually treated nonsurgically.

The next part of the test is a repeat of the first part, but in a sit­ting position. Because most women with incontinence lose urine in the standing or sitting position, this part of th e test may reveal problems that were not apparent when you were lying down. Dur­ing this part of the UDS, a test called the abdominal leak point pres­sure test is also performed. After your bladder is partly filled, you will be asked to bear down as hard as you can. The pressure gener­ated by your abdominal muscles when you bear down pushes on the bladder and increases the pressure inside the bladder. Your doctor will look to see if you lose urine and then measure the pres­sure in the bladder when this happens. If the mechanisms that normally keep you from leaking are all working, you should not leak despite the increase in pressure. If you leak just as you start to bear down, it is called a low leak point pressure. A low leak point pressure usually means that scar tissue is holding the urethra.

Our use of the term or terms Trans Vaginal Mesh Lawsuit is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Trans Vaginal Mesh Lawsuit visit our site often.

Trans Vaginal Mesh Lawsuit

Posted in Mesothelioma Cancer Law | Tagged , |

Actos Bladder Cancer Breaking News

Actos Bladder Cancer :  TURBT is often the first procedure you will have once diagnosed with a bladder tumor. This surgery is typically performed under general or spinal anesthesia as an outpatient procedure and without any incision, endoscopically through the urethra, which means a cystoscope is placed through the urethra and into the bladder. Through this scope your urologist can see the inside of your bladder and has the ability to resect, or remove, tumors in the bladder under direct vision using electrocautery. The electrocautery is also used to control bleeding after the resection is completed. TURBT is extremely important for the staging of bladder tumors but can also be therapeutic for lower stage bladder cancers. Once the tumor has been removed, it can be analyzed under the microscope by a pathologist. The pathological findings dictate further treatment decisions. If the tumor is low grade and noninvasive, you will likely not need any further therapy at this point except for close follow-up.

By and large, you can expect to go home the same day that this procedure is performed. Depending on the extent and depth of resection, your urologist may decide to send you home with a Foley catheter in place for a few days to allow time for your bladder to heal. Generally, this procedure is well tolerated, but it is not uncommon to see blood in the urine for several days after the procedure. Many patients also experience lower urinary tract symptoms, including painful urination, frequency, and urgency for up to several weeks following the procedure.

Radical cystectomy is the gold standard treatment for muscle-invasive bladder cancer and is also the procedure of choice for individuals with high-grade recurrent bladder tumors. Radical cystectomy has proven to provide excellent long-term cancer-free survival in individuals whose bladder cancer has not spread beyond their bladders or into their lymph nodes. Radical cystectomy is the therapy by which all other treatments are compared and judged.

Technically speaking, radical cystectomy for men involves removal of the bladder and prostate and also includes removal of the pelvic lymph nodes. In women, the bladder and typically the uterus, ovaries, fallopian tubes, and portions of the vagina are removed, although more recently surgeons have been moving toward preservation of some of these structures to improve quality of life. Because the main function of the bladder is to store urine that is made by the kidneys, a mechanism for diversion of urine outside of the body or storage of urine in a newly created reservoir must be performed in the same setting. Various types of urinary diversion are discussed below.

More information on Actos Bladder Cancer

Traditionally, the surgery is performed through a lower abdominal incision in the midline from just below the umbilicus (i.e., “belly button”). Hospitalization for this procedure is generally between 5 and 10 days, and up to 6 weeks are needed for complete recovery. In recent years minimally invasive surgical approaches that replicate the technique of open radical cystectomy have been developed. Both laparoscopic and robotic-assisted radical cystectomies are currently being performed at highly specialized centers. The principles of the surgery are the same, but the procedure is performed through smaller incisions using laparoscopic instruments. Using robotic assistance, your surgeon is able to perform complex operations with higher precision, under magnification. These approaches offer die potential advantage of a shorter recovery time, less blood loss, and less postoperative pain.

A pelvic lymph node dissection should be performed at the time of your surgery. This involves removal of the lymph node tissue in the most common areas of bladder cancer metastasis (spread of the cancer). The pelvic lymph node dissection has two important roles: to stage the cancer and to guide therapy. Individuals who are found to have cancer in the lymph nodes at the time of surgery generally require additional therapy such as chemotherapy. Studies have shown that up to 30 percent of patients with disease- positive lymph nodes who undergo a pelvic lymph node dissection will be free of disease at 5 years. Although there is debate among urologists as to exactiy how extensive ofapelvic lymph node dissection should be performed, there is no debate that one should be performed. Although a pelvic lymph node dissection can add an additional 30-90 minutes to your procedure time, there is little additional morbidity associated when performed by an experienced surgeon.

Regardless of the approach, anyone who undergoes a radical cystectomy will require a form of urinary diversion because the bladder will no longer be there to store urine. This can have a significant psychological and functional impact on an individual’s quality of life. Patients are often hesitant to undergo definitive surgery because of the anxiety associated with long-term urinary diversion. There are two main types of urinary diversion: continent and noncontinent. Both forms require surgically removing a segment of bowel (most commonly the small bowel) from your gastrointestinal (GI) tract and plugging the ureter from each kidney into this segment of bowel to provide drainage of urine. Noncontinent diversions (ileal conduit) are those in which the piece of bowel is brought up through the abdominal wall to a stoma and the urine drains continuously into a drainage bag. This is die most common type of urinary diversion performed in the United States. This procedure requires approximately 8 to 10 centimeters (3 to 4 inches) of small bowel, which is far less than that used for continent urinary diversions. Although the obvious disadvantage of this procedure is its lack of continence and need for a continuous drainage bag, it has less short- and long-term complications than that of the continent diversion. An external urinary drainage appliance is very well tolerated and patients adapt to them very quickly.

Information from other sources on Actos Bladder Cancer

Alternatively, a continent urinary reservoir can be reconstructed using small or large bowel. Unlike noncontinent diversions, larger segments (up to 60 cm [2 feet]) of bowel are configured into a pouch that can store urine. There are two main types of continent diversions: orthotopic and continent-cutaneous. An orthotopic continent diversion is one in which the newly reconstructed pouch is reconnected back to your urethra and voiding occurs in much the same manner as before cystectomy. Continent-cutaneous diversions use a small channel made of bowel that is brought up through the skin on the abdominal wall. Unlike the noncontinent diversions, this type of diversion does not constandy drain urine but instead collects it in the pouch. Several times a day a catheter is passed through this channel in the sldn to empty the urine from the reservoir. Although these diversions allow for urinary continence, which most replicates normal function, they are associated with increased complication rates and require much more effort to maintain compared to the ileal conduit. Additionally, multiple studies have not shown that quality of life is significantly improved with continent diversion compared to noncontinent diversion.

Sexual dysfunction after pelvic surgery can have a major impact on quality of life for both men and women. In recent years radical cystectomy with the aim of preserving sexual function has been explored in both men and women. Patients with evidence of cancer invading through the bladder wall either on preoperative imaging or at the time of surgery are not ideal candidates for this type of procedure. In men this entails sparing of die nerves involved with potency that run along and underneath the prostate. In doing so, sexual potency may be preserved in a significant percentage of men. More recently, some surgeons have explored the possibility of preserving a portion of the prostate or seminal vesicles, which are traditionally removed at the time of surgery. Preservation of these structures also decreases the risk of erectile dysfunction after surgery by not damaging the nerves that run in close proximity to diem.

Preservation of a portion of the prostate at the time of surgery also may improve continence in men undergoing an orthotopic bladder reconstruction. Although nerve sparing can be performed with little risk of decreased cancer control in appropriately selected patients, prostate- and seminal vesicle-sparing surgery are more controversial because there is potential for an increased risk of cancer recurrence and also die potential for leaving undiagnosed prostate cancer behind. In women, sexual function preserving radical cystectomy has also been explored. This involves preservation of the nerves important in both clitoral engorgement and sensation. Preserving organs traditionally removed at the time of surgery, including the uterus, fallopian tube, ovaries, and portion of vagina, may also allow for improved sexual function after surgery. It should be remembered that die first goal of surgery is cancer control, and organ- and nerve-sparing procedures may not be appropriate in all cases.

Our use of the term or terms Actos Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Bladder Cancer visit our site often.

Actos Bladder Cancer

Posted in Mesothelioma Cancer Law | Tagged , |

Multaq Warning Advice

Multaq Warning : Individuals with chronic hepatitis B infection, especially those with cirrhosis, are at increased risk for development of hepatocellular carci­noma (primary liver cancer), as in Case 5. As noted previously, while relatively rare in the United States, hepatocellular carcinoma is the num­ber one or number two cause of cancer death in the world, especially in certain Asian and African countries. Individuals with hepatitis B and cirrhosis bear the greatest risk for development of hepatocellular carci­noma. Individuals with hepatitis and no cirrhosis are also at increased risk compared to the general population.

Chronic hepatitis B infection is separated into two distinguishable “states.” The best way to distinguish these two states of hepatitis B virus infection is by the presence or absence of hepatitis Be antigen (HBeAg) in blood. In instances where the hepatitis B virus is rapidly replicating, a short form of the hepatitis B core antigen, called HBeAg, is usually detected in the blood. HBeAg is detected in the blood dur­ing acute infection, when the virus rapidly replicates, and becomes undetectable as the acute infection resolves. In most cases of chronic infection, HBeAg is not detected because the virus enters a state of low replication and its genetic material integrates into the DNA of infected cells. In some cases of chronic infection, however, the virus maintains a highly replicative “lifestyle” (are viruses alive?) and, in most of these cases HBeAg will be detected in the blood. In individuals chronically infected with hepatitis B virus, the state of infection can switch from HBeAg-positive (high replication) to HBeAg-negative (low replication) at any time.

The distinction between HBeAg-positive and HBeAg-negative chronic hepatitis B is critical regarding disease severity, prognosis, con­tagiousness, and treatment. Patients who have HBeAg in their blood usually have more severe clinical disease with a greater amount of inflammation in the liver. They are usually sicker and have more symp­toms. The chances of progression to cirrhosis and hepatocellular car­cinoma are greater. In addition, individuals with detectable HBeAg in their blood are highly infectious as high viral replication is associated with the presence of more viral particles in the blood. A major goal of treatment for chronic hepatitis B is to convert a patient who has detectable HBeAg in the blood (a state of high virus replication) to one who does not have detectable HBeAg in the blood (a state of low-level virus replication). This change after treatment is associated with a bet­ter long-term prognosis.

More information on Multaq Warning

Individuals with chronic hepatitis B virus infection can sponta­neously convert from HBeAg-negative to HBeAg-positive. This is asso­ciated with worsening disease severity and prognosis. Paradoxically, conversion from HBeAg-positive to HBeAg-negative, which is associ­ated with a better long-term outlook, is associated with a transient worsening of hepatitis and higher elevations in blood ALT and AST activities. This probably occurs because the immune system attacks the hepatocytes in which the virus is rapidly replicating, causing increased liver inflammation and cell death as infected cells are killed. The “flare” in hepatitis associated with conversion from HBeAg-positive to HBeAg-negative usually resolves with improvement in condition.

An exception to the rule that HBeAg is detectable in the blood of individuals infected with the hepatitis B virus when the virus is rapidly replicating occurs when there is infection with mutant forms of hepati­tis B virus known as precore mutants. Precore mutants of the hepati­tis B virus have mutations in their core proteins. As a result, they do not make HBeAg, even when they are rapidly replicating. Therefore, in precore mutant infection, the presence or absence of HBeAg in the blood is not a determinant of prognosis. It may be suspected when patients do not have detectable HBeAg but do have high concentra­tions of hepatitis B virus DNA in the blood. Precore mutants are defin­itively identified only by isolating the virus irony the patient and exam­ining its DNA sequence.

Information from other sources on Multaq Warning

Approximately 350 million individuals throughout the world are chronically infected with the hepatitis B virus, making it the number one worldwide cause of liver disease. The geographic distribution of cases varies tremendously from one part of the world to another. Hepatitis B virus infection is relatively uncommon in the United States and other Western countries. In the United States, just over one mil­lion individuals are chronically infected with hepatitis B virus. On the other hand, hepatitis B virus infection is endemic in Southeast Asia and sub-Saharan Africa. In countries such as Senegal, Thailand, and parts of China, as many as 25 percent of the population may become infected with hepatitis B virus by early childhood.

Transmission of hepatitis B virus from mother to baby may occur either before delivery or by exposure to the mother’s blood at the time of delivery. The hepatitis B virus is also present in the breast milk of infected mothers, but a large study has shown that breast-feeding is not a major source of transmission of hepatitis B. Some babies of infected mothers who are not infected with the hepatitis B virus at birth become infected during the first few months or first year of life—prob­ably by household exposure to the mother’s blood or that of infected brothers or sisters.

A major route of transmission of hepatitis B in the West was trans­fusion of blood and blood products. Since the association of the Aus­tralia antigen with serum hepatitis in the 1960s, tremendous efforts have been taken to screen the blood supply and keep it free of hepati­tis B virus. In most industrialized countries, the risk of contracting hepatitis B from a blood transfusion is extremely low as donated blood is screened for the virus. In addition, intravenous drug users and other individuals at high risk for hepatitis B are excluded from donating blood if they are identified. Although the blood supply is remarkably safe, no screening test is perfect, and the risk of contracting hepatitis B from a transfusion of one unit of blood in the United States is approx­imately one in sixty thousand to one in one hundred thousand. The hepatitis B virus can also be transmitted by organ transplantation, but the organ donor’s blood is generally tested for hepatitis B virus infec­tion before an organ is used.

Our use of the term or terms Multaq Warning is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Multaq Warning visit our site often.

http://www.seedol.com

Posted in Mesothelioma Cancer Law | Tagged , |